Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ACAD is in the long-term up 988% in 15 years.
Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson?s disease psychosis, and in Phase II development for Alzheimer?s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson?s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
|Shares Outstanding||EPS||-2.61||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-85.71%||Sales Growth - Q/Q||-91.67%||P/E||-10.38|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-38.09%||ROE||-40.35%||ROI|
|Current Ratio||18.01||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.06|
|Gross Margin||Operating Margin||-123217%||Net Profit Margin||-122364%||Dividend Payout Ratio|
|Cash From Financing Activities||1.44 M||Cash From Investing Activities||38.47 M||Cash From Operating Activities||-25.35 M||Gross Profit|
|Net Profit||-40.38 M||Operating Profit||-40.55 M||Total Assets||301.96 M||Total Current Assets||299.9 M|
|Total Current Liabilities||16.65 M||Total Debt||Total Liabilities||16.87 M||Total Revenue|
|High 52 week||39.14||Low 52 week||15.12||Last close||17.87||Last change||1.53%|
|RSI||52.92||Average true range||0.66||Beta||1.75||Volume||3.38 M|
|Simple moving average 20 days||0.08%||Simple moving average 50 days||-2.47%||Simple moving average 200 days||-35.73%|
|Performance Week||2.47%||Performance Month||-2.14%||Performance Quart||-30.98%||Performance Half||-40.61%|
|Performance Year||-34.78%||Performance Year-to-date||-40.65%||Volatility daily||1.95%||Volatility weekly||4.36%|
|Volatility monthly||8.94%||Volatility yearly||30.98%||Relative Volume||1230.89%||Average Volume||2.95 M|
|New High||New Low|
2019-06-13 08:02:53 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
2019-06-11 20:23:24 | Is ACADIA Pharmaceuticals Inc. ACAD A Good Stock To Buy?
2019-06-11 08:03:44 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
2019-06-11 06:59:38 | When Will ACADIA Pharmaceuticals Inc. NASDAQ:ACAD Turn A Profit?
2019-06-10 08:02:57 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
2019-06-06 08:02:52 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
2019-06-04 08:02:55 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
2019-05-18 11:00:00 | ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
2019-05-08 15:30:00 | Why Acadia Pharmaceuticals Stock Slumped in April
2019-05-07 08:05:40 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
2019-05-02 03:24:18 | Acadia Pharmaceuticals ACAD Q1 2019 Earnings Call Transcript
2019-05-02 01:20:53 | Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT
2019-05-01 19:35:11 | Acadia Pharmaceuticals ACAD Reports Q1 Loss, Tops Revenue Estimates
2019-05-01 18:29:19 | Acadia: 1Q Earnings Snapshot
2019-05-01 16:05:00 | ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
2019-04-30 08:03:55 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
2019-04-29 21:58:12 | Were Hedge Funds Right About Flocking Into ACADIA Pharmaceuticals Inc. ACAD?
2019-04-26 06:10:23 | Analysts point to potential Biogen M&A options after Alzheimer's failure
2019-04-19 09:11:16 | Should ACADIA Pharmaceuticals NASDAQ:ACAD Be Disappointed With Their -30% Profit?
2019-04-17 09:00:00 | ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
2019-04-09 10:45:45 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
2019-03-29 07:20:00 | Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
2019-03-26 08:22:11 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
2019-03-21 06:30:00 | HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
2019-03-13 13:18:04 | Is ACADIA Pharmaceuticals Inc.’s NASDAQ:ACAD Liquidity Good Enough?
2019-03-05 14:36:00 | Why Acadia Pharmaceuticals Stock Perked Up in February
2019-02-27 20:21:28 | Edited Transcript of ACAD earnings conference call or presentation 26-Feb-19 10:00pm GMT
2019-02-27 09:30:00 | 3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks
2019-02-27 01:05:40 | Acadia Pharmaceuticals Inc ACAD Q4 2018 Earnings Conference Call Transcript
2019-02-26 16:05:00 | ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-26 13:28:31 | Big Pharma faces the Senate in drug price hearings
2019-02-15 16:08:09 | What's in the Cards for Bausch Health BHC Q4 Earnings?
2019-02-14 12:58:05 | 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
2019-02-13 08:15:00 | New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
2019-02-11 16:51:09 | Zoetis ZTS to Report Q4 Earnings: What's in the Cards?
2019-02-11 15:58:08 | Is a Disappointment in Store for Incyte INCY Q4 Earnings?
2019-02-08 16:56:09 | Tilray TLRY to Report Q4 Earnings: What's in the Cards?
2019-02-08 08:07:05 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.